Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis’s Chief Medical Officer On All Things MS And The Science Of Operations

Executive Summary

Shreeram Aradhye, Novartis’s Global Head, Medical Affairs, and Chief Medical Officer (Pharmaceuticals), outlines the company’s all-encompassing-approach for multiple sclerosis therapies. In a wide-ranging interview with Scrip, Aradhye also touches on the promise of gene therapy and how emerging technologies are helping shape medical innovation.


Related Content

Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?
Novartis’s Luxturna Deal Expands Gene Therapy Ambitions
What's Gilead Getting From Kite For Nearly $12bn?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts